Board of Directors
LENA DEGLING WIKINGSSON, PhD (Chairman)
Lena Degling Wikingsson is a pharmacist by training and holds a PhD in Pharmaceutical Science. She nearly 20 years of experience in the pharmaceutical industry and has previously been CEO of Independent Pharmaceutica AB and Avaris AB , a non-executive Director of Avaris AB, held positions at SBL Vaccines, Accuro Immunology, and was biotechnology assessor at the Medicinal Products Agency. She has broad experience in regulatory affairs and development of biologics and vaccines as well as extensive experience in small companies in life science. Lena Degling Wikingsson is currently non-executive Director of Simplexia and Eurocine Vaccines and CEO of Dilafor AB.
GUNNAR MATTSON, LL.M
Gunnar Mattsson is Partner at Lindahl Advokatbyrå and has 20 years experience primarily in corporate law, venture capital and Swedish and international contracts. Mr Mattsson is chairman of the Life Sciences group at Lindahl and works with pharmaceuticals, biotech, diagnostics and medical technology. He is ranked in Life Sciences by both Chambers Europe and PLC.
KATARINA LE BLANC, MD, Professor
Professor in Clinical Stem Cell Research at Karolinska Institutet. Professor Le Blanc has pioneered research and clinical use of cell therapies. Prof Le Blanc’s main research interest is mesenchymal stromal cells and their immunoregulatory properties for which she has received several distinguished awards.
JOHNNY GREINSMARK, MBA
Extensive experience from financial reporting and corporate governance in both public, private and EU funded organizations.
CECILIA GÖTHERSTRÖM, PhD
Associate Professor in Stem Cell Research at Karolinska Institutet and holds a Senior Researcher position at Clinical Science, Intervention and Technology (CLINTEC), Division of Obstetrics and Gynecology. Dr Götherström has a research group at Center for Hematology and Regenerative Medicine (HERM) and manages the National Umbilical Cord Blood bank at Karolinska University Hospital. She coordinates the BOOSTB4 project with the aim to treat Osteogenesis Imperfecta with fetal mesenchymal stem cells.